Dataset Information

Genetic and phenotypic spectrum associated with IFIH1 gain-of-function.

ABSTRACT: IFIH1 gain-of-function has been reported as a cause of a type I interferonopathy encompassing a spectrum of autoinflammatory phenotypes including Aicardi-Goutières syndrome and Singleton Merten syndrome. Ascertaining patients through a European and North American collaboration, we set out to describe the molecular, clinical and interferon status of a cohort of individuals with pathogenic heterozygous mutations in IFIH1. We identified 74 individuals from 51 families segregating a total of 27 likely pathogenic mutations in IFIH1. Ten adult individuals, 13.5% of all mutation carriers, were clinically asymptomatic (with seven of these aged over 50 years). All mutations were associated with enhanced type I interferon signaling, including six variants (22%) which were predicted as benign according to multiple in silico pathogenicity programs. The identified mutations cluster close to the ATP binding region of the protein. These data confirm variable expression and nonpenetrance as important characteristics of the IFIH1 genotype, a consistent association with enhanced type I interferon signaling, and a common mutational mechanism involving increased RNA binding affinity or decreased efficiency of ATP hydrolysis and filament disassembly rate.

SUBMITTER: Rice GI

PROVIDER: S-EPMC7457149 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Genetic and phenotypic spectrum associated with IFIH1 gain-of-function.

Rice Gillian I GI Park Sehoon S Gavazzi Francesco F Adang Laura A LA Ayuk Loveline A LA Van Eyck Lien L Seabra Luis L Barrea Christophe C Battini Roberta R Belot Alexandre A Berg Stefan S Billette de Villemeur Thierry T Bley Annette E AE Blumkin Lubov L Boespflug-Tanguy Odile O Briggs Tracy A TA Brimble Elise E Dale Russell C RC Darin Niklas N Debray François-Guillaume FG De Giorgis Valentina V Denecke Jonas J Doummar Diane D Drake Af Hagelsrum Gunilla G Eleftheriou Despina D Estienne Margherita M Fazzi Elisa E Feillet François F Galli Jessica J Hartog Nicholas N Harvengt Julie J Heron Bénédicte B Heron Delphine D Kelly Diedre A DA Lev Dorit D Levrat Virginie V Livingston John H JH Marti Itxaso I Mignot Cyril C Mochel Fanny F Nougues Marie-Christine MC Oppermann Ilena I Pérez-Dueñas Belén B Popp Bernt B Rodero Mathieu P MP Rodriguez Diana D Saletti Veronica V Sharpe Cia C Tonduti Davide D Vadlamani Gayatri G Van Haren Keith K Tomas Vila Miguel M Vogt Julie J Wassmer Evangeline E Wiedemann Arnaud A Wilson Callum J CJ Zerem Ayelet A Zweier Christiane C Zuberi Sameer M SM Orcesi Simona S Vanderver Adeline L AL Hur Sun S Crow Yanick J YJ

Human mutation 20200114 4

IFIH1 gain-of-function has been reported as a cause of a type I interferonopathy encompassing a spectrum of autoinflammatory phenotypes including Aicardi-Goutières syndrome and Singleton Merten syndrome. Ascertaining patients through a European and North American collaboration, we set out to describe the molecular, clinical and interferon status of a cohort of individuals with pathogenic heterozygous mutations in IFIH1. We identified 74 individuals from 51 families segregating a total of 27 like ...[more]

PMID: 31898846

Similar Datasets

Project description:BACKGROUND: Sodium channel NaV1.7 is preferentially expressed within dorsal root ganglia (DRG), trigeminal ganglia and sympathetic ganglion neurons and their fine-diamter axons, where it acts as a threshold channel, amplifying stimuli such as generator potentials in nociceptors. Gain-of-function mutations and variants (single amino acid substitutions) of NaV1.7 have been linked to three pain syndromes: Inherited Erythromelalgia (IEM), Paroxysmal Extreme Pain Disorder (PEPD), and Small Fiber Neuropathy (SFN). IEM is characterized clinically by burning pain and redness that is usually focused on the distal extremities, precipitated by mild warmth and relieved by cooling, and is caused by mutations that hyperpolarize activation, slow deactivation, and enhance the channel ramp response. PEPD is characterized by perirectal, periocular or perimandibular pain, often triggered by defecation or lower body stimulation, and is caused by mutations that severely impair fast-inactivation. SFN presents a clinical picture dominated by neuropathic pain and autonomic symptoms; gain-of-function variants have been reported to be present in approximately 30% of patients with biopsy-confirmed idiopathic SFN, and functional testing has shown altered fast-inactivation, slow-inactivation or resurgent current. In this paper we describe three patients who house the NaV1.7/I228M variant. METHODS: We have used clinical assessment of patients, quantitative sensory testing and skin biopsy to study these patients, including two siblings in one family, in whom genomic screening demonstrated the I228M NaV1.7 variant. Electrophysiology (voltage-clamp and current-clamp) was used to test functional effects of the variant channel. RESULTS: We report three different clinical presentations of the I228M NaV1.7 variant: presentation with severe facial pain, presentation with distal (feet, hands) pain, and presentation with scalp discomfort in three patients housing this NaV1.7 variant, two of which are from a single family. We also demonstrate that the NaV1.7/I228M variant impairs slow-inactivation, and produces hyperexcitability in both trigeminal ganglion and DRG neurons. CONCLUSION: Our results demonstrate intra- and interfamily phenotypic diversity in pain syndromes produced by a gain-of-function variant of NaV1.7.

Dataset Information

Genetic and phenotypic spectrum associated with IFIH1 gain-of-function.

Publications

Genetic and phenotypic spectrum associated with IFIH1 gain-of-function.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets